Product Description
Mechanisms of Action: rRNA Blocker,Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular,Intravenous,Oral,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Belgium | Canada | China | France | Germany | Hong Kong | Ireland | Luxembourg | Malaysia | Morocco | New Zealand | Norway | Pakistan | Poland | Portugal | Singapore | South Africa | Spain | Taiwan | Tunisia | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|